Literature DB >> 16341949

Treatment of gastroesophageal reflux disease.

Michael Pettit1.   

Abstract

UNLABELLED: AIM OF THE REVIEW AND METHODS: This review brings together information on the treatment of gastroesophageal reflux disease. Published manuscripts were identified from Medline. The articles were then screened for relevance prior to inclusion in the review. RESULTS AND
CONCLUSION: Up to 40% of people in Western countries are estimated to regularly experience heartburn, the most characteristic symptom of gastroesophageal reflux disease (GERD). Treatment options available for GERD range from over-the-counter (OTC) antacids to proton pump inhibitors (PPIs) and anti-reflux surgery. Many patients self-medicate with OTC medications such as antacids and low-dose histamine H2-receptor antagonists (H2RA) to relieve episodic or food-related symptoms of GERD, and may not seek medical advice unless symptoms persist or worsen. However, GERD is a chronic disease that frequently affects health-related quality of life and, if not properly managed, the complications of GERD may include erosive oesophagitis (EO), Barrett's oesophagus and adenocarcinoma. Adequate control of acid secretion is key to the successful treatment of the condition. OTC medications provide effective symptom relief to about one quarter of patients suffering from GERD. H2RAs can also provide effective symptomatic relief, particularly in patients with milder GERD, but become less-effective over time. PPIs are the agents of choice for the suppression of gastric acid production and have become the mainstay of therapy for acid-related diseases. PPIs produce significantly faster and more complete symptomatic relief, significantly faster and more complete healing of erosive GERD compared with H2RAs and are also significantly more effective at preventing relapse of EO. There are a number of existing guidelines for the treatment of GERD. Recommendation for initial therapy consist of general measures, such as lifestyle advice in combination with antacids and/or alginates. When general measures fail, the next step is empirical therapy. Two options exist for the expirical treatment of GERD, so-called "step-up" or "step-down" therapy. There are no clear data to support either treatment strategy as a universal approach to all patients; consequently, physicians must always choose the course best suited to the individual patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16341949     DOI: 10.1007/s11096-005-4798-7

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  25 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Gastro-oesophageal reflux disease in adults: Guidelines for clinicians.

Authors:  Peter Katelaris; Richard Holloway; Nicholas Talley; David Gotley; Steven Williams; John Dent
Journal:  J Gastroenterol Hepatol       Date:  2002-08       Impact factor: 4.029

Review 3.  Management of severe gastroesophageal reflux disease.

Authors:  J A DiPalma
Journal:  J Clin Gastroenterol       Date:  2001-01       Impact factor: 3.062

Review 4.  Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.

Authors:  J Q Huang; R H Hunt
Journal:  Best Pract Res Clin Gastroenterol       Date:  2001-06       Impact factor: 3.043

5.  Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis.

Authors:  J G Hatlebakk; A Berstad
Journal:  Scand J Gastroenterol       Date:  1996-10       Impact factor: 2.423

6.  [Prevalence of gastro-oesophageal reflux disease in general practice].

Authors:  M Hollenz; M Stolte; J Labenz
Journal:  Dtsch Med Wochenschr       Date:  2002-05-10       Impact factor: 0.628

7.  Loss of acid suppression during dosing with H2-receptor antagonists.

Authors:  C Wilder-Smith; F Halter; T Ernst; M Gennoni; B Zeyen; L Varga; J J Roehmel; H S Merki
Journal:  Aliment Pharmacol Ther       Date:  1990       Impact factor: 8.171

Review 8.  Effect of omeprazole on gastric acid secretion and plasma gastrin in man.

Authors:  L Olbe; C Cederberg; T Lind; M Olausson
Journal:  Scand J Gastroenterol Suppl       Date:  1989

Review 9.  The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease.

Authors:  D G Colin-Jones
Journal:  Aliment Pharmacol Ther       Date:  1995       Impact factor: 8.171

10.  Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology.

Authors:  K R DeVault; D O Castell
Journal:  Arch Intern Med       Date:  1995-11-13
View more
  8 in total

Review 1.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

2.  Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials.

Authors:  Soo-Kyung Kim; Peter Fristrup; Ravinder Abrol; William A Goddard
Journal:  J Chem Inf Model       Date:  2011-11-16       Impact factor: 4.956

3.  Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?

Authors:  William D Chey; Reema R Mody; Esin Izat
Journal:  Dig Dis Sci       Date:  2010-04-17       Impact factor: 3.199

4.  A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.

Authors:  Abdallah A Kobeissy; Jana G Hashash; Faek R Jamali; Assaad M Skoury; Reham Haddad; Sarah El-Samad; Rami Ladki; Rola Aswad; Assaad M Soweid
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

5.  Aerophagia and gastroesophageal reflux disease in patients using continuous positive airway pressure: a preliminary observation.

Authors:  Nathaniel F Watson; Sue K Mystkowski
Journal:  J Clin Sleep Med       Date:  2008-10-15       Impact factor: 4.062

6.  Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants.

Authors:  Hamid Reza Azizollahi; Mandana Rafeey
Journal:  Korean J Pediatr       Date:  2016-05-31

7.  Comparison of paracetamol and diclofenac prescribing preferences for adults in primary care.

Authors:  Dilara Bayram; Volkan Aydin; Abdullah Sanli; Mustafa Naci Abanoz; Busra Sibic; Sedat Pala; Omer Atac; Ahmet Akici
Journal:  Prim Health Care Res Dev       Date:  2021-12-02       Impact factor: 1.458

Review 8.  Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden.

Authors:  S J Panchal; P Müller-Schwefe; J I Wurzelmann
Journal:  Int J Clin Pract       Date:  2007-05-04       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.